Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405746 | 0.88 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2CA14CYP2C19KMT2A | |
| SCHEMBL10464095 | 0.83 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL27853893 | 0.82 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2CA14CYP2C19KMT2A | |
| SCHEMBL18643781 | 0.80 | — | — | |
| SCHEMBL5404644 | 0.80 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL21578228 | 0.78 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2CA14MEN1KMT2A | |
| SCHEMBL6701923 | 0.78 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16209947 | 0.74 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11418641 | 0.73 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2CA14CYP2C19KMT2A | |
| SCHEMBL17089318 | 0.73 | CA5A (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258349-B2 | Anti-viral drug | DORING INTERNATIONAL GMBH (CH) | 2025-03-25 | — | — | US | disclosed |
| EP-3419627-B1 | PROCESS FOR THE MANUFACTURE OF ANTIVIRAL COMPOUNDS, SUCH AS TRIAZAVIRIN | DORING INT GMBH (CH) | 2023-07-12 | — | — | EP | disclosed |
| EP-3419627-B1 | PROCESS FOR THE MANUFACTURE OF ANTIVIRAL COMPOUNDS, SUCH AS TRIAZAVIRIN | DORING INT GMBH (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20220298164-A1 | ANTI-VIRAL DRUG | DORING INTERNATIONAL GMBH (CN) | 2022-09-22 | — | — | US | disclosed |
| US-11370797-B2 | Anti-viral drug | DORING INTERNATIONAL GMBH (CH) | 2022-06-28 | — | — | US | disclosed |
| US-20200325143-A1 | ANTI-VIRAL DRUG | DORING INTERNATIONAL GMBH (CH) | 2020-10-15 | — | — | US | disclosed |
| US-20190055256-A1 | ANTI-VIRAL DRUG | DORING INTERNATIONAL GMBH (CH) | 2019-02-21 | — | — | US | disclosed |
| EP-3419627-A2 | ANTI-VIRAL DRUG | Doring International GmbH (CH) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017144709-A1 | ANTI-VIRAL DRUG | DORING INTERNATIONAL GMBH (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144708-A2 | ANTI-VIRAL DRUG | DORING INTERNATIONAL GMBH (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144708-A2 | ANTI-VIRAL DRUG | DORING INTERNATIONAL GMBH (CH) | 2017-08-31 | — | — | WO | disclosed |
| US-8835470-B2 | Mandelamide heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20130045964-A1 | MANDELAMIDE HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-21 | — | — | US | disclosed |
| US-8354398-B2 | Substituted isoxazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110300165-A1 | SUBSTITUTED ISOXAZOLE COMPOUNDS | The Board of TRustees of the University of Illinoi University of Illinios (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298164-A1 | ANTI-VIRAL DRUG | ZC3HAV1, ZC3HAV1L, SARS1 | ALDH1A1 1309/4885SMN1; SMN2 2218/4885CA14 885/4885 |
| US-11370797-B2 | Anti-viral drug | NSUN3, EIF2AK2, NSUN2 | ALDH1A1 1794/4885SMN1; SMN2 498/4885CA14 3687/4885 |
| US-20200325143-A1 | ANTI-VIRAL DRUG | NSUN3, EIF2AK2, NSUN2 | ALDH1A1 1794/4885SMN1; SMN2 498/4885CA14 3687/4885 |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | ALDH1A1 3119/4885SMN1; SMN2 1771/4885CA14 4832/4885 |
| US-20190055256-A1 | ANTI-VIRAL DRUG | EIF2AK2, NSUN3, NSUN2 | ALDH1A1 1485/4885SMN1; SMN2 332/4885CA14 4446/4885 |
| US-20110300165-A1 | SUBSTITUTED ISOXAZOLE COMPOUNDS | S1PR4, S1PR3, S1PR1 | ALDH1A1 1558/4885SMN1; SMN2 3484/4885CA14 4182/4885 |
| US-20130045964-A1 | MANDELAMIDE HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | ALDH1A1 2189/4885SMN1; SMN2 1302/4885CA14 4611/4885 |
| US-12258349-B2 | Anti-viral drug | ZC3HAV1, ZC3HAV1L, SARS1 | ALDH1A1 1309/4885SMN1; SMN2 2218/4885CA14 885/4885 |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | S1PR1, S1PR4, S1PR3 | ALDH1A1 2144/4885SMN1; SMN2 3076/4885CA14 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.